What is the recommended treatment for an adult with liposarcoma?

Treatment of Liposarcoma in Adults

Surgery with wide excision and negative margins (R0 resection) is the cornerstone of treatment for localized liposarcoma, and must be performed by a surgeon specifically trained in sarcoma management at a specialized center. 1, 2

Localized Disease Management

Surgical Approach

• Wide en bloc resection is mandatory, removing the tumor with all adherent organs in a single specimen 1, 2
• For retroperitoneal liposarcomas specifically, complete compartmental resection is critical because normal retroperitoneal fat is indistinguishable from well-differentiated tumor 3, 4
• Re-excision by an expert team is required if initial surgery was inadequate or performed outside a reference center 1
• Marginal R1 resections may be acceptable only for atypical lipomatous tumors/well-differentiated liposarcomas in anatomically challenging locations 1

Radiation Therapy

Radiotherapy should be added for high-grade (G2-3), deep, >5 cm lesions 1, 2

• RT may be omitted for G1, R0, <5cm, superficial tumors 1
• Neoadjuvant RT is NOT standard of care for retroperitoneal liposarcoma based on the STRASS trial showing no benefit in abdominal recurrence-free survival 5, 3
• However, post-hoc analysis suggests neoadjuvant RT may benefit specific liposarcoma subtypes—this remains investigational 5
• Myxoid liposarcoma is the most radiosensitive subtype 6

Chemotherapy for Localized Disease

• Adjuvant chemotherapy is NOT standard treatment 2
• Neoadjuvant chemotherapy with anthracyclines plus ifosfamide for ≥3 cycles can be considered as an option in high-risk patients, particularly when tumor shrinkage could reduce surgical morbidity 2
• Well-differentiated liposarcomas are generally chemo-resistant and should be observed if large or difficult to resect, unless dedifferentiation is suspected 3, 7

Advanced/Metastatic Disease

Surgical Management of Metastases

• Metachronous resectable lung metastases (disease-free interval ≥1 year) without extrapulmonary disease should be surgically resected if complete excision is feasible 8, 2, 8
• Synchronous lung metastases or extrapulmonary disease require chemotherapy as standard treatment 8

First-Line Systemic Therapy

The treatment approach differs dramatically by liposarcoma subtype:

For dedifferentiated, myxoid/round cell, and pleomorphic liposarcomas:

• Anthracycline-based chemotherapy is first-line standard treatment 8, 2, 8
• Multi-agent chemotherapy with doxorubicin plus ifosfamide is preferred when tumor response is needed and performance status is good 8, 2, 8
• Single-agent doxorubicin is acceptable when combination therapy is not tolerated 8

For well-differentiated liposarcomas:

• These are chemo-resistant; systemic therapy is generally not effective 3, 7
• Close surveillance is preferred unless dedifferentiation occurs 3, 7

For myxoid liposarcomas specifically:

• These are relatively chemo-sensitive 6, 7
• Consider trabectedin early, as this subtype shows particularly high response rates 8

Second-Line and Beyond

Trabectedin is the preferred second-line option for liposarcomas, particularly effective in myxoid and dedifferentiated subtypes 1, 8, 2, 8

Eribulin is specifically approved and recommended for liposarcomas (excluding well-differentiated) after doxorubicin failure 1, 2, 9

• This is based on survival benefit demonstrated in a randomized trial 2, 9

Additional second-line options include:

• High-dose ifosfamide (12-14 g/m²/cycle) if not previously used or to overcome resistance 1, 8
• Gemcitabine-based combinations (with docetaxel or dacarbazine), though NOT recommended as first-line 1, 2

Pazopanib should be AVOIDED in adipogenic/liposarcoma subtypes 1, 8

• It is only an option for non-adipogenic soft tissue sarcomas 1, 2, 8

Emerging and Experimental Therapies

For well-differentiated and dedifferentiated liposarcomas with MDM2 amplification and CDK4 overexpression:

• MDM2 antagonists and CDK4/6 inhibitors are under investigation in clinical trials 6, 7
• Enrollment in histotype-specific trials should be strongly encouraged 10, 7

Critical Pitfalls to Avoid

1. Do not treat all liposarcomas the same—subtype determines treatment sensitivity and prognosis 7, 11
2. Do not use pazopanib for liposarcomas—it is contraindicated in adipogenic sarcomas 1, 8
3. Do not perform surgery outside specialized sarcoma centers—this leads to inadequate resections requiring re-excision 1, 2
4. Do not give routine neoadjuvant RT for retroperitoneal liposarcoma—STRASS trial showed no benefit 5, 3
5. Do not use gemcitabine/docetaxel as first-line therapy—it is not recommended 1, 2

Subtype-Specific Summary

• Well-differentiated: Surgery only; observe if unresectable; chemo-resistant 3, 7
• Dedifferentiated: Surgery + RT for localized; anthracyclines ± ifosfamide for metastatic; trabectedin or eribulin second-line 1, 2, 3
• Myxoid/round cell: Surgery + RT for localized (most radiosensitive); chemo-sensitive; trabectedin particularly effective 8, 6, 7
• Pleomorphic: Surgery + RT for localized; chemo-sensitive; anthracyclines first-line; eribulin second-line 2, 6, 7